Back to search results

Calcium Carbonate to Help Labor Contractions

This study is looking at whether Calcium Carbonate 500 MG can help improve contractions during labor. Researchers believe it might assist the labor induction process. You might be able to join if you are 18 or older, pregnant with your first child (nulliparas), at least 36 weeks pregnant, and are having your labor induced or augmented (strengthened). The study aims to see if Calcium Carbonate leads to better contractions, more vaginal deliveries, and improved delivery outcomes. The main goals for this study are to see how many people are interested, how many join, and how many complete the treatment as planned.

Study design
This is an interventional study with a planned enrollment of 60 women. The phase of the study is not specified.
What's involved
Participants will take Calcium Carbonate 500 MG orally every 4 hours, or receive standard-dose synthetic oxytocin. Adherence to the intervention will be measured during hospitalization, for approximately 5 days.
Compensation
Not stated in the trial record.
Follow-up
The study measures participant adherence during hospitalization, which is approximately 5 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06580782

Calcium Carbonate to Augment Labor Contractions

Recruiting
PHASE4Ages 18+InterventionalTreatment
Weill Medical College of Cornell University
~60 participants
Updated 2025-10-23 on ClinicalTrials.gov
What's tested:Calcium Carbonate 500 MGStandard Dose Synthetic Pitocin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants Consented
Measured over Day 0
+2 more outcomes measured

Conditions

Labor Dystocia
Labor Induction
Labor Augmentation

Explore related trials

Augmentation of LaborDysfunctional LaborInduction of LaborPregnancy

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Moeun Son, MD · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University

Who to contact

Ester Sanchez, BSN
[email protected]
212-746-2106
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years or older
Nulliparas (no prior pregnancy lasting 20 weeks or greater of gestation)
Gestational age above 36 weeks, at enrollment
Present for induction or augmentation of labor inclusive of medical indication, elective induction at greater than 39 weeks' gestation, trial of labor after cesarean
Singleton gestation (a multiple gestation reduced to a singleton, either spontaneously or therapeutically, before 14 0/7 weeks of gestation is acceptable)
Ability to give informed consent
Planned to undergo initiation of oxytocin infusion by their maternity care provider

Exclusion

Unable to understand or read English
Presence of tachysystole (defined as more than 5 contractions in 10 minutes averaged over 30 minutes), recurrent variable or late fetal decelerations, and bradycardia in the prior 30 minutes before enrollment
Non-vertex presenting fetus at enrollment
Planned for cesarean delivery or contraindication to labor by institutional policy (e.g., placenta previa, vasa previa, active genital herpes infection, previous transmural myomectomy)
Multi-fetal gestation (twins, triplets, and higher order multiples)
Known contraindication to taking calcium carbonate including renal calculus, high urine calcium levels, elevated serum calcium, low serum phosphate, achlorhydria, or suspected digoxin toxicity.
Deliveries with fetal chronic and/or pregnancy-related conditions, IUFD (Intra Uterine Fetal Death) or premature \< 36 weeks of gestation.
Major fetal anomaly suspected prenatally (defined as a fetal anomaly with anticipated neonatal intensive care unit admission)
Suspected alloimmunization (given the increased likelihood for anticipated neonatal intensive care unit admission)
Known severe fetal growth restriction (estimated fetal weight \<3rd percentile) or abnormal umbilical artery Doppler studies (given the increased likelihood for anticipated neonatal intensive care unit admission)
Participation in another interventional study that influences management of labor and delivery or perinatal morbidity or mortality
Known allergic reactions to synthetic oxytocin intravenous solution or to Calcium Carbonate
Significantly impaired consciousness or executive function (e.g., intubated or sedated)
Patients treated with calcium channel blockers such as nifedipine or magnesium.
Chronic renal failure and hyperphosphatemia.
Inability to tolerate oral intake (i.e., nausea/vomiting)

What this trial measures

  • Number of Participants ConsentedDay 0

    RedCAP is used to track the consent rates to determine the feasibility of a larger randomized controlled trial.

  • Number of Participants EnrolledDay 0

    RedCAP is used to track the enrollment rates to determine the feasibility of a larger randomized controlled trial.

  • Number of Participants that complete the Intervention as prescribed (Adherence)During hospitalization, approximately 5 days

    RedCAP is used to track the adherence rates to determine the feasibility of a larger randomized controlled trial.